Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website https://www.jofem.org

Original Article

Volume 10, Number 3-4, August 2020, pages 89-93


Sodium-Glucose Co-Transporter 2 Inhibitors Increase Serum Level of Total Procollagen Type 1 Amino-Terminal Propeptide and Bone Strength in Japanese Patients With Type 2 Diabetes Mellitus

Tables

Table 1. Characteristics of Patients Enrolled in the Study
 
Data are expressed as mean ± SD. SD: standard deviation; BMI: body mass index; HbA1c: hemoglobin A1c; DPP4: dipeptidyl peptidase 4.
Number of patients19
Male/female16/3
Age (years)66 ± 12
Body weight(kg)73.7 ± 10.9
BMI (kg/m2)26.6 ± 3.2
HbA1c (%)7.4 ± 1.1
Concomitant medication
  Anti-diabetic drug (n)
    Biguanide6
    Sulfonylurea1
    Insulin1
    Alpha-glucosidase inhibitor5
    Thiazolidinedione3
    DPP4-inhibitor10
  Lipid-modifying agents (n)13
  Antihypertensive drug (n)13

 

Table 2. Effects of Six Months’ Administration of SGLT2 Inhibitors on the Body Weight, BMI, HbA1c, and Glucose- and Lipid-Metabolic Parameters
 
Before administrationAfter 6 months’ administration
Data are expressed as mean ± SD. *P < 0.05, **P < 0.01 vs. before administration. SD: standard deviation; BMI: body mass index; HbA1c: hemoglobin A1c; SGLT2: sodium-glucose co-transporter 2; LDL: low-density lipoprotein; HDL: high-density lipoprotein.
Body weight (kg)73.7 ± 10.970.6 ± 11.2**
BMI (kg/m2)26.6 ± 3.225.5 ± 3.2**
HbA1c (%)7.4 ± 1.16.8 ± 0.8*
Blood glucose (mg/dL)115 ± 3698 ± 17*
Serum total cholesterol (mg/dL)190 ± 30187 ± 23
Serum LDL-cholesterol (mg/dL)112 ± 26111 ± 20
Serum HDL-cholesterol (mg/dL)52 ± 1059 ± 9**
Serum triglyceride (mg/dL)186 ± 94117 ± 67**

 

Table 3. Effects of Six Months’ Administration of SGLT2 Inhibitors on Bone Strength, Bone Density and Bone Metabolism-Related Parameters
 
Before administrationAfter 6 months’ administration
Data are expressed as mean ± SD. *P < 0.05 vs. before administration. Bone strength and density are expressed as the comparison with those in young adult means. QUS: quantitative ultrasound; DEXA: dual-energy X-ray absorptiometry; SD: standard deviation; SGLT2: sodium-glucose co-transporter 2.
Bone strength measured by QUS
  Calcaneal bone (%)88 ± 1691 ± 15*
Bone density measured by DEXA
  Lumbar spine (%)109 ± 13106 ± 12
  Femur (%)87 ± 1383 ± 10
Serum total P1NP (µg/L)35.2 ± 10.339.0 ± 12.8*
Serum TRACP-5b (mU/dL)215 ± 62245 ± 82